JPH09504108A - 早産防止治療をモニターするためのエストリオール測定の利用 - Google Patents
早産防止治療をモニターするためのエストリオール測定の利用Info
- Publication number
- JPH09504108A JPH09504108A JP7511752A JP51175295A JPH09504108A JP H09504108 A JPH09504108 A JP H09504108A JP 7511752 A JP7511752 A JP 7511752A JP 51175295 A JP51175295 A JP 51175295A JP H09504108 A JPH09504108 A JP H09504108A
- Authority
- JP
- Japan
- Prior art keywords
- estriol
- concentration
- preterm birth
- prevention treatment
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.早産防止治療をモニタリングする方法であって: 早産防止剤による治療を経験することについての候補として診断された又はこ れを経験している妊娠患者の体液中のエストリオールの最初の濃度を計測し;そ の最初の濃度と事前決定された標準エストリオール値とを関係付け;そしてその 最初の濃度及びその事前決定されたエストリオール値に対するその関係付けに基 づいて、早産防止治療を開始するか、継続するか、中止するか、又は修正するか のいずれかを行う、 ことを含んで成る方法。 2.前記関係付けが、(1)正常妊娠ヒト中の体液についてのエストリオール 濃度の事前決定レンジ又は (2)妊娠ヒトの体液の前もって計測されたエストリオール濃度、 からなる群から選ばれた標準値と前記濃度を比較することを含んで成る、請求項 1に記載の方法。 3.標準値に対して高い濃度のエストリオールが、早産防止治療の開始、継続 、又は強さの増加の指標として利用される、請求項1に記載の方法。 4.標準値未満又はこれと等しいエストリオールの濃度が、早産防止治療の中 止又は減少として利用される、請求項1に記載の方法。 5.最初のエストリオール濃度が、標準よりも高く、そして早産防止治療が開 始、継続、又は増加され、そしてそのエストリオール濃度が、その濃度がその標 準よりも低い事前決定第2エストリオール濃度に達するまで、一定時間にわたり 計測される、請求項1に記 載の方法。 6.決定が患者の体液のサンプルについて行われる、請求項1に記載の方法。 7.体液が、唾液、血漿、血清、尿、子宮頸又は膣分泌物、あるいは汗である 、請求項6に記載の方法。 8.体液が唾液であり、そしてその濃度が、その濃度が5nMを超えるとき早産 防止治療の開始、継続、又は増加の指標と考えられ、そしてその濃度が3nM未満 であるとき早産防止治療の中止又は減少の指標と考えられる、請求項6に記載の 方法。 9.前記方法が早産防止治療前に行われ、そし前記濃度が、早産防止治療が開 始されて1週間以内に、50%程、妊娠ヒトにおける体液中で得られた先に計測さ れたエストリオール濃度を超える、請求項1に記載の方法。 10.前記方法が早産防止治療前に行われ、そして前記濃度が、少なくとも40週 目における正常妊娠について体液についての第95百分位数濃度と同じ程に高く、 そして早産防止治療が開始されて30週目又はそれより早期においてその濃度が計 測される、請求項1に記載の方法。 11.前記方法が非結合エストリオールだけを検出する、請求項1に記載の方法 。 12.前記方法が、早産防止治療の開始後に行われ、そして早産防止治療が、そ の濃度が標準値を1標準偏差以下上廻る計測値に達するときに中止される、請求 項1に記載の方法。 13.前記方法が、早産防止治療の開始後に行われ、そして早産防止治療が、そ の濃度が標準値を1標準偏差以下下廻る計測値に達するときに中止される、請求 項1に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/136,219 | 1993-10-13 | ||
US08/136,219 US5370135A (en) | 1993-10-13 | 1993-10-13 | Use of estriol measurement to monitor tocolytic therapy |
PCT/US1994/007892 WO1995010779A1 (en) | 1993-10-13 | 1994-07-14 | Use of estriol measurement to monitor tocolytic therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09504108A true JPH09504108A (ja) | 1997-04-22 |
JP3522762B2 JP3522762B2 (ja) | 2004-04-26 |
Family
ID=22471884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51175295A Expired - Fee Related JP3522762B2 (ja) | 1993-10-13 | 1994-07-14 | 早産防止治療をモニターするためのエストリオール測定の利用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US5370135A (ja) |
EP (1) | EP0723666B1 (ja) |
JP (1) | JP3522762B2 (ja) |
AU (1) | AU7332794A (ja) |
DE (1) | DE69406302T2 (ja) |
HK (1) | HK1001596A1 (ja) |
WO (1) | WO1995010779A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011210230A (ja) * | 2010-03-26 | 2011-10-20 | General Electric Co <Ge> | 医療情報のグラフ表示のためのシステム及び方法 |
JP2019500351A (ja) * | 2016-01-04 | 2019-01-10 | オブセヴァ エス.エー. | ヒドロキシプロピルチアゾリジンカルボキサミド誘導体のアルファ−アミノエステル及びその塩形態、結晶多形 |
US11524003B2 (en) | 2016-01-04 | 2022-12-13 | ObsEva S.A. | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
US11534428B1 (en) | 2018-05-16 | 2022-12-27 | Xoma (Us) Llc | Compositions and methods for delaying the incidence of labor |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996003929A1 (en) * | 1994-08-04 | 1996-02-15 | Biex, Inc. | Method for prediction of premature delivery using estetrol (e4) as an indicator |
US5804452A (en) * | 1995-04-27 | 1998-09-08 | Quidel Corporation | One step urine creatinine assays |
AU2247997A (en) * | 1996-01-29 | 1997-08-20 | Savor, Evelyn P. | Method of treating undesired uterine contractions using optically pure R-or RR-isomers of adrenergic beta-2 agonists |
US6087090A (en) * | 1997-02-25 | 2000-07-11 | Celtrix Pharmaceuticals, Inc. | Methods for predicting drug response |
US5824467A (en) * | 1997-02-25 | 1998-10-20 | Celtrix Pharmaceuticals | Methods for predicting drug response |
SG102538A1 (en) | 1998-04-24 | 2004-03-26 | Roche Diagnostics Gmbh | Storage container for analytical devices |
CA2348910A1 (en) * | 1998-10-29 | 2000-05-11 | Kirk L. Ives | Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation |
US6174665B1 (en) | 1999-09-10 | 2001-01-16 | Biex, Inc. | Hormone replacement therapy monitoring |
AU2738401A (en) * | 1999-12-29 | 2001-07-09 | Aeron Biotechnology, Inc. | Saliva assay for steroid hormones |
EP1936376B1 (en) | 2003-02-06 | 2012-04-11 | Hologic Inc. | Screening and treatment methods for prevention of preterm delivery |
US7399278B1 (en) | 2003-05-05 | 2008-07-15 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Method and system for measuring amniotic fluid volume and/or assessing fetal weight |
WO2005007223A2 (en) * | 2003-07-16 | 2005-01-27 | Sasha John | Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations |
EP1652145B1 (en) * | 2003-08-06 | 2015-10-07 | TRIG Medical Ltd. | Method for monitoring labor parameters |
US20060024722A1 (en) * | 2004-07-30 | 2006-02-02 | Mark Fischer-Colbrie | Samples for detection of oncofetal fibronectin and uses thereof |
US7776557B2 (en) * | 2006-01-30 | 2010-08-17 | Diagnostic Technologies Ltd. | Method for monitoring tocolytic treatment |
EP2544707B1 (en) * | 2010-03-09 | 2018-11-21 | Dignity Health | Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening |
EP2632471B1 (en) * | 2010-10-27 | 2019-05-01 | Dignity Health | Trimegestone (tmg) for treatment of preterm birth |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4500523A (en) * | 1983-03-15 | 1985-02-19 | Cornell Research Foundation, Inc. | Suppression of premature labor by use of aromatase inhibitors |
-
1993
- 1993-10-13 US US08/136,219 patent/US5370135A/en not_active Expired - Lifetime
-
1994
- 1994-07-14 EP EP94923473A patent/EP0723666B1/en not_active Expired - Lifetime
- 1994-07-14 JP JP51175295A patent/JP3522762B2/ja not_active Expired - Fee Related
- 1994-07-14 DE DE69406302T patent/DE69406302T2/de not_active Expired - Lifetime
- 1994-07-14 WO PCT/US1994/007892 patent/WO1995010779A1/en active IP Right Grant
- 1994-07-14 AU AU73327/94A patent/AU7332794A/en not_active Abandoned
-
1998
- 1998-01-21 HK HK98100523A patent/HK1001596A1/xx not_active IP Right Cessation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011210230A (ja) * | 2010-03-26 | 2011-10-20 | General Electric Co <Ge> | 医療情報のグラフ表示のためのシステム及び方法 |
JP2019500351A (ja) * | 2016-01-04 | 2019-01-10 | オブセヴァ エス.エー. | ヒドロキシプロピルチアゾリジンカルボキサミド誘導体のアルファ−アミノエステル及びその塩形態、結晶多形 |
US11524003B2 (en) | 2016-01-04 | 2022-12-13 | ObsEva S.A. | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
JP2023002668A (ja) * | 2016-01-04 | 2023-01-10 | オブセヴァ エス.エー. | ヒドロキシプロピルチアゾリジンカルボキサミド誘導体のアルファ-アミノエステル及びその塩形態、結晶多形 |
US11534428B1 (en) | 2018-05-16 | 2022-12-27 | Xoma (Us) Llc | Compositions and methods for delaying the incidence of labor |
Also Published As
Publication number | Publication date |
---|---|
JP3522762B2 (ja) | 2004-04-26 |
AU7332794A (en) | 1995-05-04 |
WO1995010779A1 (en) | 1995-04-20 |
HK1001596A1 (en) | 1998-06-26 |
EP0723666B1 (en) | 1997-10-15 |
DE69406302D1 (de) | 1997-11-20 |
US5370135A (en) | 1994-12-06 |
DE69406302T2 (de) | 1998-03-19 |
EP0723666A1 (en) | 1996-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3522762B2 (ja) | 早産防止治療をモニターするためのエストリオール測定の利用 | |
Anumba et al. | Nitric oxide activity in the peripheral vasculature during normotensive and preeclamptic pregnancy | |
Chapman et al. | Systemic and renal hemodynamic changes in the luteal phase of the menstrual cycle mimic early pregnancy | |
US10408838B2 (en) | Non-invasive biomarker to identify subject at risk of preterm delivery | |
Reiter et al. | Hypertension in pregnancy: the incidence of underlying renal disease and essential hypertension | |
WO1996003929A1 (en) | Method for prediction of premature delivery using estetrol (e4) as an indicator | |
Pedersen et al. | Plasma noradrenaline and adrenaline in pre-eclampsia, essential hypertension in pregnancy and normotensive pregnant control subjects | |
Brown et al. | Low-dose aspirin: II. Relationship of angiotensin II pressor responses, circulating eicosanoids, and pregnancy outcome | |
Koullapis et al. | Plasma prostanoids in pregnancy‐induced hypertension | |
EP1979749A1 (en) | A method for determining the effectiveness of a treatment for preeclampsia | |
Clark et al. | Urinary cyclic GMP, endothelin, and prostaglandin E2 in normal pregnancy and preeclampsia | |
McCoshen et al. | Prostaglandin E2 release on the fetal and maternal sides of the amnion and chorion-decidua before and after term labor | |
Sogani et al. | Estimation of thyroid hormones levels in preeclamptic pregnant women: an early predictor of the disease | |
Zammit et al. | Preeclampsia: the effects of serum on endothelial cell prostacyclin, endothelin, and cell membrane integrity | |
Bodelsson et al. | Reduced contractile effect of endothelin-1 and noradrenalin in human umbilical artery from pregnancies with abnormal umbilical artery flow velocity waveforms | |
Pedersen et al. | Renin, angiotensin II, aldosterone, catecholamines, prostaglandins and vasopressin. The importance of pressor and depressor factors for hypertension in pregnancy | |
Hayashi et al. | Prospective study of angiotensin II response to positional change in pregnancy-induced hypertension | |
Karumanchi | Pregnancy and the Kidney | |
Dekker | Prediction and prevention of pregnancy-induced hypertensive disorders: a clinical and pathophysiologic study | |
Marlettini et al. | Role of prolactin in pregnancy hypertension | |
Mastrogiannis et al. | Cocaine decreases urinary prostacyclin release in pregnancy: correlation with uterine and umbilical Doppler velocimetry | |
Lateef | Thyroid Hormone Changes in Early Pregnancy Bleeding Versus Normal Healthy Pregnancy | |
JPS63106557A (ja) | 分娩の切迫を決定する方法 | |
EP0930879B1 (en) | Use of calcium dobesilate for the manufacture of a medicament for the treatment of embryonic retardation | |
Ii et al. | Effect of Low-Dose Aspirin on Platelet Angiotensin II Binding and on the Pressor Response To |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20031218 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040106 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040205 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090220 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090220 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100220 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100220 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110220 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120220 Year of fee payment: 8 |
|
LAPS | Cancellation because of no payment of annual fees |